E-Mail
IMAGE: Kenneth Grossmann, MD, PhD, of Huntsman Cancer Institute, led the SWOG S1404 clinical trial, which found that patients with high-risk melanoma who had pembrolizumab after their surgery had a longer. view more
Credit: Huntsman Cancer Institute
PORTLAND, OR - Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021.
Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients three and one-half years after the last patient enrolled to the trial. They did find, however, that patients taking pembrolizumab had fewer serious side effects than those treated with either high-dose in
SWOG researchers to present practice-changing research at virtual ASCO 2021 SWOG always brings an impressive portfolio of work to the ASCO annual meeting, said SWOG Chair Charles D. Blanke, MD, and this year I m particularly excited about the research our investigators are presenting because it includes results that are likely to be practice-changing.
Investigators will present 12 abstracts from SWOG-led or co-led studies and 11 abstracts from studies led by other groups within the National Clinical Trials Network (NCTN).
Results from S1216 will be presented orally by study chair Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah. S1216 compared androgen deprivation therapy (ADT) combined with TAK-700 to the standard treatment of ADT with bicalutamide in patients who had metastatic hormone-sensitive prostate cancer. The study found that adding TAK-700 to ADT lengthened median progression-free survival in these patients and improved prostate-specific
UCLA Health
Dr. Jeffrey Eckardt pioneered a type of surgery that replaced amputation for people with bone cancer.
A new endowed chair at UCLA will honor the memory of Dr. Jeffrey Eckardt, a longtime faculty member who pioneered limb salvage surgery.
The chair is funded by gifts totaling more than $1 million from 42 foundations, families and individuals, including many who were Eckardt’s friends and former colleagues. The David Geffen School of Medicine at UCLA received lead gifts from Maxine and Eugene Rosenfeld, the Leonetti/O’Connell Family Foundation, Jean-Marc Chapus, and Christine and Steven F. Udvar-Hazy.
The medical school named Dr. Nicholas Bernthal the inaugural Jeffrey J. Eckardt, M.D., Professor of Orthopaedic Surgery.